E. A. Leontyeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. A. Leontyeva has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Andrey A. Baranov
Yaroslavl State Medical University
4 shared publications - Natalia A. Lapkina
Yaroslavl State Medical University
4 shared publications - Alexander S. Artyuhov
N.I. Pirogov Russian National Research Medical University
3 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
3 shared publications - Natalia E. Abaytova
Yaroslavl State Medical University
3 shared publications - Natalya Yaltseva
Yaroslavl State Medical University
3 shared publications
Latest Publications
- Open Access
- 23 October 2025
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 7-14
Efficacy of vortioxetine in the comprehensive treatment o women with obesity and affective disorders: results of a comparative study
SUMMARY Obesity remains a pressing issue as a multidisciplinary condition with a significant psychoemotional component. Objective. To assess the clinical and psychoemotional status of female patients with exogenous-constitutional obesity and comorbid affective disorders, as well as to determine the efficacy of incorporating vortioxetine into the comprehensive treatment regimen. Materials and Methods. The study included 66 women aged 39 to 46 years with obesity (BMI 35–40 kg/m²). The main group (n=34) received vortioxetine 10–20 mg/day alongside standard obesity therapy (diet and physical activity); the comparison group (n=32) declined pharmacological treatment but followed endocrinologist recommendations. Assessment included anthropometric measurements, biochemical and hormonal analyses, and psychometric evaluations using the Hamilton Depression Rating Scale (HDRS‑17) and Hamilton Anxiety Rating Scale (HARS) at baseline, 3 months, and 6 months. Results. Both groups exhibited a high prevalence of depressive and anxiety disorders ranging from mild episodes to mixed states and dysthymia. By month 6, the main group demonstrated a statistically significant reduction in depression and anxiety levels: average HDRS scores decreased from 19.0 to 9.9, and HARS scores from 16.3 to 7.9. No significant changes in psychoemotional status were observed in the comparison group. Body weight reduction was more pronounced in the vortioxetine group, while the comparison group had a higher rate of treatment refusal (34.4 %). Conclusion. The use of vortioxetine in women with obesity and affective disorders leads to an improvement in psychoemotional status and may contribute to the correction of metabolic disturbances.
- 23 October 2025
- Published by Alfmed LLC in Medical alphabet
- No. 21,p. 7-14
Open AccessEfficacy of vortioxetine in the comprehensive treatment o women with obesity and affective disorders: results of a comparative study
SUMMARY Obesity remains a pressing issue as a multidisciplinary condition with a significant psychoemotional component. Objective. To assess the clinical and psychoemotional status of female patients with exogenous-constitutional obesity and comorbid affective disorders, as well as to determine the efficacy of incorporating vortioxetine into the comprehensive treatment regimen. Materials and Methods. The study included 66 women aged 39 to 46 years with obesity (BMI 35–40 kg/m²). The main group (n=34) received vortioxetine 10–20 mg/day alongside standard obesity therapy (diet and physical activity); the comparison group (n=32) declined pharmacological treatment but followed endocrinologist recommendations. Assessment included anthropometric measurements, biochemical and hormonal analyses, and psychometric evaluations using the Hamilton Depression Rating Scale (HDRS‑17) and Hamilton Anxiety Rating Scale (HARS) at baseline, 3 months, and 6 months. Results. Both groups exhibited a high prevalence of depressive and anxiety disorders ranging from mild episodes to mixed states and dysthymia. By month 6, the main group demonstrated a statistically significant reduction in depression and anxiety levels: average HDRS scores decreased from 19.0 to 9.9, and HARS scores from 16.3 to 7.9. No significant changes in psychoemotional status were observed in the comparison group. Body weight reduction was more pronounced in the vortioxetine group, while the comparison group had a higher rate of treatment refusal (34.4 %). Conclusion. The use of vortioxetine in women with obesity and affective disorders leads to an improvement in psychoemotional status and may contribute to the correction of metabolic disturbances.
- Open Access
- 24 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 96-104
Pleiotropic effects of osteoarthritis therapy
The article discusses the problem of osteoarthritis, its increasing prevalence and high comorbidity. The data on the effect of osteoarthritis on the course of comorbid conditions, as well as the influence of a number of common diseases, such as hypertension on the development of osteoarthritis, are presented. In matters of therapy, data are provided on the effectiveness of the use of glucosamine, chondroitin sulfate and diacerein. The article presents the results of studies demonstrating the pleiotropic properties of these molecules. Thus, the most important pleiotropic effects of glucosamine include a preventive role in the development of atherosclerosis, an effect on reducing the risk of general cardiovascular events by 15% and the risk of individual cardiovascular events by 9–22%. Glucosamine intake is also associated with a reduced risk of lung cancer and mortality from lung cancer. The results of large cohort studies demonstrated that glucosamine use was associated with a 17% reduction in the risk of developing DM2, as well as a lower risk of developing gout in women and a lower risk of developing dementia. The use of chondroitin sulfate increased the bone mineral density of rats with diabetes mellitus, and also relieved the symptoms of hyperglycemia, polydipsia and polyphagia caused by diabetes in rats. The article also presents the results of a study that demonstrated significant inhibition of HCT-116 xenograft tumor development in mice by suppressing proliferation and inducing apoptosis while taking chondroitin sulfate. In other studies, it has demonstrated the ability to reduce oxidative stress and increase the amount of antioxidants that are important for neuroregeneration. The use of diacerein helps to increase insulin secretion and improve metabolic control in patients with type 2 diabetes mellitus. Thus, regular intake of glucosamine, chondroitin sulfate and diacerein can affect comorbid conditions, improving their course, as well as reduce cardiovascular risks.
- 24 December 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 22,p. 96-104
Open AccessPleiotropic effects of osteoarthritis therapy
The article discusses the problem of osteoarthritis, its increasing prevalence and high comorbidity. The data on the effect of osteoarthritis on the course of comorbid conditions, as well as the influence of a number of common diseases, such as hypertension on the development of osteoarthritis, are presented. In matters of therapy, data are provided on the effectiveness of the use of glucosamine, chondroitin sulfate and diacerein. The article presents the results of studies demonstrating the pleiotropic properties of these molecules. Thus, the most important pleiotropic effects of glucosamine include a preventive role in the development of atherosclerosis, an effect on reducing the risk of general cardiovascular events by 15% and the risk of individual cardiovascular events by 9–22%. Glucosamine intake is also associated with a reduced risk of lung cancer and mortality from lung cancer. The results of large cohort studies demonstrated that glucosamine use was associated with a 17% reduction in the risk of developing DM2, as well as a lower risk of developing gout in women and a lower risk of developing dementia. The use of chondroitin sulfate increased the bone mineral density of rats with diabetes mellitus, and also relieved the symptoms of hyperglycemia, polydipsia and polyphagia caused by diabetes in rats. The article also presents the results of a study that demonstrated significant inhibition of HCT-116 xenograft tumor development in mice by suppressing proliferation and inducing apoptosis while taking chondroitin sulfate. In other studies, it has demonstrated the ability to reduce oxidative stress and increase the amount of antioxidants that are important for neuroregeneration. The use of diacerein helps to increase insulin secretion and improve metabolic control in patients with type 2 diabetes mellitus. Thus, regular intake of glucosamine, chondroitin sulfate and diacerein can affect comorbid conditions, improving their course, as well as reduce cardiovascular risks.
- 21 July 2024
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (10) , 31-36
Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors
Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role in the pathogenesis of RA. JAK inhibitors and bDMARD are aimed at suppressing various pathological reactions caused by them.The aim of the study. To determine the effect of therapy with JAK and IL-6 inhibitors on the concentration of proinflammatory cytokines in RA patients in real clinical practice.Materials and methods. The study included 30 patients with a reliable diagnosis of RA, advanced stage of disease, with moderate or high RA activity and ineffectiveness of previous therapy with csDMARD or bDMARD for at least 6 months. 10 patients received TOFA at a dose of 5 mg twice daily 10 received UPA at a dose of 15 mg once daily and 10 were on OKZ therapy at a dose of 64 mg subcutaneously every 4 weeks. Studies were performed before treatment, after 3 and 6 months of therapy. The levels of IL-1β, IL-6, IL-17A, IL-17F, IL-23, IL-31, IL-33, INF-γ, TNF-α in serum were investigated using multiplex xMAR technology on Bio-PlexTM 200 System analyser (BIO-RAD, USA).Results. In all groups of patients after 3 and 6 months from the start of therapy, there was a significant decrease in the RA activity index compared to baseline values. The concentration of IL-1β, IL-17A, IL-17F and IL-23 did not change significantly during treatment with any of the drugs. IL-6 values on TOFA background significantly decreased after 3 and 6 months of follow-up compared to the baseline level. UPA therapy had no effect on IL-6 level during the whole observation period, and against the background of OKZ application its values significantly increased after 3 months, and after 6 months – decreased, remaining higher than the initial values. The concentration of IL-31 after 3 months of TOFA treatment significantly decreased (respectively: 6.95 (3.85; 17.72) pg/ml and 3.00 (1.50; 3.85) pg/ml, pConclusions. The use of TOFA, UPA and OKZ in RA patients has a positive effect on disease activity, but has different effects on the level of proinflammatory cytokines in serum.
- 21 July 2024
- Published by Alfmed LLC in Medical alphabet
- Vol. 1 (10) , 31-36
Proinflammatory cytokines in rheumatoid arthritis: dynamics against therapy with Janus kinase and interleukin 6 inhibitors
Increased production of proinflammatory cytokines in serum and synovial fluid plays an important role in the pathogenesis of RA. JAK inhibitors and bDMARD are aimed at suppressing various pathological reactions caused by them.The aim of the study. To determine the effect of therapy with JAK and IL-6 inhibitors on the concentration of proinflammatory cytokines in RA patients in real clinical practice.Materials and methods. The study included 30 patients with a reliable diagnosis of RA, advanced stage of disease, with moderate or high RA activity and ineffectiveness of previous therapy with csDMARD or bDMARD for at least 6 months. 10 patients received TOFA at a dose of 5 mg twice daily 10 received UPA at a dose of 15 mg once daily and 10 were on OKZ therapy at a dose of 64 mg subcutaneously every 4 weeks. Studies were performed before treatment, after 3 and 6 months of therapy. The levels of IL-1β, IL-6, IL-17A, IL-17F, IL-23, IL-31, IL-33, INF-γ, TNF-α in serum were investigated using multiplex xMAR technology on Bio-PlexTM 200 System analyser (BIO-RAD, USA).Results. In all groups of patients after 3 and 6 months from the start of therapy, there was a significant decrease in the RA activity index compared to baseline values. The concentration of IL-1β, IL-17A, IL-17F and IL-23 did not change significantly during treatment with any of the drugs. IL-6 values on TOFA background significantly decreased after 3 and 6 months of follow-up compared to the baseline level. UPA therapy had no effect on IL-6 level during the whole observation period, and against the background of OKZ application its values significantly increased after 3 months, and after 6 months – decreased, remaining higher than the initial values. The concentration of IL-31 after 3 months of TOFA treatment significantly decreased (respectively: 6.95 (3.85; 17.72) pg/ml and 3.00 (1.50; 3.85) pg/ml, pConclusions. The use of TOFA, UPA and OKZ in RA patients has a positive effect on disease activity, but has different effects on the level of proinflammatory cytokines in serum.
- Open Access
- 31 October 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (5) , 554-561
Experience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes
The aim of the study was to evaluate in real clinical practice the effectiveness of therapy with an interleukin-6 inhibitor (olokizumab) in patients with rheumatoid arthritis (RA) in terms of clinical and laboratory activity of the disease, as well as patient-reported outcomes (PROs). Material and methods. 10 patients with a reliable diagnosis of RA were examined: the average age of the patients was 45.70±17.9 years, the duration of the disease was 9.0 (3.0; 12.0) years. Patients were with moderate or high disease activity: DAS28-ESR – 5.13 (4.34; 5.80) points; CDAI – 30.00 (24.00; 35.00); SDAI – 31.86 (24.36; 38,59). All patients were prescribed treatment with olokizumab (OKZ) at a dose of 64 mg subcutaneously every 4 weeks against the background of therapy with methotrexate, leflunomide, non-steroidal anti-inflammatory drugs and glucocorticoids (GC) (up to 10 mg/day in terms of prednisolone). Three patients had previously received tocilizumab (intravenously once a month at a dose of 8 mg/kg), the administration of which was discontinued for administrative reasons 6–12 months before the appointment of OKZ. The results of treatment were assessed by the dynamics of clinical, laboratory parameters (DAS28-ESR, SDAI, СDAI, CRP, ESR, IgM RF, ACCP) and outcomes assessed by the patients themselves (PROs): HAQ-DI index, general assessment of the health status of patients (OSZB) according to VAS, pain according to VAS; scales FACIT, SF-36. As psychometric methods, the questionnaire “Type of attitude towards the disease (TOBOL)”, the Hospital Anxiety and Depression Scale (HADS), and the Toronto Alexithymic Scale (TAS-26) were used. Observation was carried out before treatment, after 3 and 6 months of therapy. Results. Against the background of OKZ therapy, after 3 and 6 months, compared with the baseline, there was a significant decrease in the clinical indices of RA activity: DAS28-ESR – 5.13 (4.34; 5.80), 3.53 (2.83; 4.26) and 3.48 (2.8; 4.10) points respectively; CDAI – 30.00 (24.00; 35.00), 11.00 (6.0; 16.00) and 10.0 (5.0; 15.0) points respectively; SDAI – 31.86 (24.36; 38.59), 11.05 (6.07; 16.07) and 10.17 (7.02; 15.02) points respectively; CRP – 14.30 (7.00; 24.70), 0.70 (0.40; 0.90) and 0.65 (0.20; 3.0) mg/l respectively. No significant dynamics of ESR, RF IgM and ACCP was noted. After 3 and 6 months of treatment with OKZ, there was a significant decrease in OSZB and pain severity according to the VAS scale, and an improvement in the functional state of patients was observed according to the HAQ-DI questionnaire of fatigue indicators (FACIT-F) (pConclusion. In general, the results of this study indicate the effectiveness of ICD in RA, not only in terms of reducing the clinical and laboratory activity of the disease, but also in terms of outcomes reported by the patient himself, characterizing the quality of life and the psycho-emotional state of patients.
- 31 October 2023
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 61 (5) , 554-561
Open AccessExperience with the interleukin 6 inhibitor (Olokizumab) in patients with rheumatoid arthritis in real clinical practice: Influence on inflammatory activity and disease outcomes
The aim of the study was to evaluate in real clinical practice the effectiveness of therapy with an interleukin-6 inhibitor (olokizumab) in patients with rheumatoid arthritis (RA) in terms of clinical and laboratory activity of the disease, as well as patient-reported outcomes (PROs). Material and methods. 10 patients with a reliable diagnosis of RA were examined: the average age of the patients was 45.70±17.9 years, the duration of the disease was 9.0 (3.0; 12.0) years. Patients were with moderate or high disease activity: DAS28-ESR – 5.13 (4.34; 5.80) points; CDAI – 30.00 (24.00; 35.00); SDAI – 31.86 (24.36; 38,59). All patients were prescribed treatment with olokizumab (OKZ) at a dose of 64 mg subcutaneously every 4 weeks against the background of therapy with methotrexate, leflunomide, non-steroidal anti-inflammatory drugs and glucocorticoids (GC) (up to 10 mg/day in terms of prednisolone). Three patients had previously received tocilizumab (intravenously once a month at a dose of 8 mg/kg), the administration of which was discontinued for administrative reasons 6–12 months before the appointment of OKZ. The results of treatment were assessed by the dynamics of clinical, laboratory parameters (DAS28-ESR, SDAI, СDAI, CRP, ESR, IgM RF, ACCP) and outcomes assessed by the patients themselves (PROs): HAQ-DI index, general assessment of the health status of patients (OSZB) according to VAS, pain according to VAS; scales FACIT, SF-36. As psychometric methods, the questionnaire “Type of attitude towards the disease (TOBOL)”, the Hospital Anxiety and Depression Scale (HADS), and the Toronto Alexithymic Scale (TAS-26) were used. Observation was carried out before treatment, after 3 and 6 months of therapy. Results. Against the background of OKZ therapy, after 3 and 6 months, compared with the baseline, there was a significant decrease in the clinical indices of RA activity: DAS28-ESR – 5.13 (4.34; 5.80), 3.53 (2.83; 4.26) and 3.48 (2.8; 4.10) points respectively; CDAI – 30.00 (24.00; 35.00), 11.00 (6.0; 16.00) and 10.0 (5.0; 15.0) points respectively; SDAI – 31.86 (24.36; 38.59), 11.05 (6.07; 16.07) and 10.17 (7.02; 15.02) points respectively; CRP – 14.30 (7.00; 24.70), 0.70 (0.40; 0.90) and 0.65 (0.20; 3.0) mg/l respectively. No significant dynamics of ESR, RF IgM and ACCP was noted. After 3 and 6 months of treatment with OKZ, there was a significant decrease in OSZB and pain severity according to the VAS scale, and an improvement in the functional state of patients was observed according to the HAQ-DI questionnaire of fatigue indicators (FACIT-F) (pConclusion. In general, the results of this study indicate the effectiveness of ICD in RA, not only in terms of reducing the clinical and laboratory activity of the disease, but also in terms of outcomes reported by the patient himself, characterizing the quality of life and the psycho-emotional state of patients.
- Open Access
- 11 November 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (5) , 554-559
IL-31 and IL-33 in rheumatoid arthritis patients
Objective – to investigate clinical and diagnostic significance of IL-31 and IL-33 determination in patients with rheumatoid arthritis (RA).Material and methods. 154 patients with a reliable diagnosis of RA were examined. Serum levels of IL-31 and IL-33 were studied using multiplex xMAP technology on Bio-PlexTM 200 System analyzer (BIO-RAD, USA). The upper limit of the norm in the study of 20 healthy donor sera was (M+3σ): IL-31 – 15.08 pg/ml, IL-33 – 3.40 pg/ml.Results. IL-31 (Me (25th; 75th percentile) – 13.75 (5.63; 308.52) and 6.10 (2.87; 8.62) pg/ml (p< 0.001), IL-33 – 18.86 (7.45; 65.95) and 0.52 (0.17; 0.78) pg/ml (p< 0.001) levels were observed in RA patients in comparison with the control group. An increase in IL-33 concentration (more than 3.40 pg/ml) was observed in 87.0% of patients, and IL-31 (more than 15.08 pg/ml) in 48.1% of patients with RA. An increase in IL-33 alone was observed in 42.2% (65 of 154 patients) with RA, while an isolated increase in IL-31 concentration was observed in only 2 (1.3%) patients. Simultaneous hyperproduction of IL-33 and IL-31 occurred in 69 (44.9%) patients. We revealed positive correlation of clinical and laboratory parameters of RA with cytokine concentration: SDAI correlated with IL-33 (r=0.36; p< 0.05); CRP – with IL-31 (r=0.49; p< ,05) and IL-33 (r=0.40; p<0.05)Conclusion. Concentrations of IL-31 and IL-33 are elevated in RA patients and correlate with the indices of inflammatory activity of the disease.
- 11 November 2022
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 60 (5) , 554-559
Open AccessIL-31 and IL-33 in rheumatoid arthritis patients
Objective – to investigate clinical and diagnostic significance of IL-31 and IL-33 determination in patients with rheumatoid arthritis (RA).Material and methods. 154 patients with a reliable diagnosis of RA were examined. Serum levels of IL-31 and IL-33 were studied using multiplex xMAP technology on Bio-PlexTM 200 System analyzer (BIO-RAD, USA). The upper limit of the norm in the study of 20 healthy donor sera was (M+3σ): IL-31 – 15.08 pg/ml, IL-33 – 3.40 pg/ml.Results. IL-31 (Me (25th; 75th percentile) – 13.75 (5.63; 308.52) and 6.10 (2.87; 8.62) pg/ml (p< 0.001), IL-33 – 18.86 (7.45; 65.95) and 0.52 (0.17; 0.78) pg/ml (p< 0.001) levels were observed in RA patients in comparison with the control group. An increase in IL-33 concentration (more than 3.40 pg/ml) was observed in 87.0% of patients, and IL-31 (more than 15.08 pg/ml) in 48.1% of patients with RA. An increase in IL-33 alone was observed in 42.2% (65 of 154 patients) with RA, while an isolated increase in IL-31 concentration was observed in only 2 (1.3%) patients. Simultaneous hyperproduction of IL-33 and IL-31 occurred in 69 (44.9%) patients. We revealed positive correlation of clinical and laboratory parameters of RA with cytokine concentration: SDAI correlated with IL-33 (r=0.36; p< 0.05); CRP – with IL-31 (r=0.49; p< ,05) and IL-33 (r=0.40; p<0.05)Conclusion. Concentrations of IL-31 and IL-33 are elevated in RA patients and correlate with the indices of inflammatory activity of the disease.
- Open Access
- 27 December 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (6) , 693-699
Dynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy
Objective - to study the dynamics of clinical and laboratory parameters of inflammatory activity of the disease and cytokines in rheumatoid arthritis (RA) patients on a background of tofacitinib (TOFA) treatment.Material and methods. Ten patients with a reliable diagnosis of RA have been examined: patients' age was 51.0 (48.0; 62.0) years, duration of disease was 7.0 (3.0; 20.0) years. All patients had high disease activity: DAS28 -5.88 (5.53; 5.94), CDAI - 33.0 (29.0; 36.0), SDAI - 33.72 (30.75; 36.85). All patients were treated with TOFA at a dose of 5 mg 2 times a day on a background of methotrexate therapy, non-steroidal anti-inflammatory drugs, and glucocorticoids. Observations were performed before treatment and after 3 and 6 months of therapy. Serum levels of 15 cytokines (IL-1β, IL-4, IL-6, TNF-α, INF-γ, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L) were examined using multiplex xMAP technology.After 3 and 6 months of TOFA therapy, there was a significant decrease in DAS28 of 4.55 (3.47; 5.16) and 3.92 (3.80; 4.60); CDAI - 16.5 (11.0; 23.0) and 18.0 (15.0; 19.0); SDAI - 16.6 (11.23; 23.06) and 18.07 (15.06; 19.10); ESR - 19.0 (11.0; 26.0) and 7.0 (4.0; 18.0); CRP - 0.56 (0.50; 1.99) and 0.71 (0.51; 1.1) respectively. IL-6 levels decreased after 3 and 6 months of therapy (pppConclusion. The results of the study show the efficacy of TOFA in RA and create prerequisites for further study of the cytokine-dependent mechanisms of inflammation in this disease.
- 27 December 2021
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (6) , 693-699
Open AccessDynamics of clinical manifestations and cytokine concentrations in rheumatoid arthritis patients on tofacitinib therapy
Objective - to study the dynamics of clinical and laboratory parameters of inflammatory activity of the disease and cytokines in rheumatoid arthritis (RA) patients on a background of tofacitinib (TOFA) treatment.Material and methods. Ten patients with a reliable diagnosis of RA have been examined: patients' age was 51.0 (48.0; 62.0) years, duration of disease was 7.0 (3.0; 20.0) years. All patients had high disease activity: DAS28 -5.88 (5.53; 5.94), CDAI - 33.0 (29.0; 36.0), SDAI - 33.72 (30.75; 36.85). All patients were treated with TOFA at a dose of 5 mg 2 times a day on a background of methotrexate therapy, non-steroidal anti-inflammatory drugs, and glucocorticoids. Observations were performed before treatment and after 3 and 6 months of therapy. Serum levels of 15 cytokines (IL-1β, IL-4, IL-6, TNF-α, INF-γ, IL-10, IL-17A, IL-17F, IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, sCD40L) were examined using multiplex xMAP technology.After 3 and 6 months of TOFA therapy, there was a significant decrease in DAS28 of 4.55 (3.47; 5.16) and 3.92 (3.80; 4.60); CDAI - 16.5 (11.0; 23.0) and 18.0 (15.0; 19.0); SDAI - 16.6 (11.23; 23.06) and 18.07 (15.06; 19.10); ESR - 19.0 (11.0; 26.0) and 7.0 (4.0; 18.0); CRP - 0.56 (0.50; 1.99) and 0.71 (0.51; 1.1) respectively. IL-6 levels decreased after 3 and 6 months of therapy (pppConclusion. The results of the study show the efficacy of TOFA in RA and create prerequisites for further study of the cytokine-dependent mechanisms of inflammation in this disease.